⚖️ CPSC issues 5 recalls this week; bike helmets, ranges, steamers flagged

Determination of Attainment by the Attainment Date But for International Emissions for the 2015 Ozone National Ambient Air Quality Standards; Phoenix-Mesa Nonattainment Area, Arizona

EPA has issued a determination that the <strong>Phoenix-Mesa nonattainment area</strong> in Arizona would have attained the <strong>2015 ozone NAAQS</strong> by the attainment date but for international emissions contributions. The determination applies specifically to ozone levels attributed to pollution sources outside U.S. borders.

Approval of Clean Air Plans; San Joaquin Valley, California; Contingency Measures for 1997 Ozone Standards

EPA has approved contingency measures in the <strong>San Joaquin Valley, California</strong> State Implementation Plan for the <strong>1997 ozone standards</strong>. The approval addresses required backup emission reduction measures in the event the area fails to meet attainment milestones.

Air Plan Approval; Texas; Reasonably Available Control Technology in the Dallas-Fort Worth Ozone Nonattainment Area

EPA has approved <strong>Reasonably Available Control Technology (RACT)</strong> requirements for the <strong>Dallas-Fort Worth ozone nonattainment area</strong> in Texas. The air plan approval establishes technology-based emission controls for volatile organic compounds and nitrogen oxides in the region.

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) , PHASE3

<strong>AbbVie</strong> has completed the <strong>TRANSFORM-1 Phase 3</strong> clinical trial evaluating <strong>navitoclax</strong> in combination with ruxolitinib versus ruxolitinib alone in subjects with myelofibrosis. The randomized, double-blind, placebo-controlled study assessed the combination therapy's efficacy in treating the rare blood cancer.

A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) , PHASE2, PHASE3

<strong>Pfizer</strong> has completed a long-term, open-label <strong>Phase 2/Phase 3</strong> follow-up study of <strong>tofacitinib</strong> for treatment of <strong>juvenile idiopathic arthritis (JIA)</strong>. The trial evaluated the safety and efficacy of extended tofacitinib therapy in pediatric patients with the chronic inflammatory joint condition.

Product Recall: Aisstxoer Adult Bike Helmets

<strong>Aisstxoer Adult Bike Helmets</strong> have been recalled due to product safety concerns. The recall affects adult bicycle helmets sold under the Aisstxoer brand name.

Product Recall: Frigidaire Gas Ranges

<strong>Frigidaire Gas Ranges</strong> are subject to a product recall. The recall involves gas cooking ranges manufactured under the Frigidaire brand.

Product Recall: Goregent Infant Walkers

<strong>Goregent Infant Walkers</strong> have been recalled due to safety issues. The recall affects infant mobility products sold under the Goregent brand name.

Market Context